Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.
[powerpress]
Logo
You are here
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Related Content
Article
Published April 6, 2012 | By Dr West | 6 Comments
Article
Did you recently receive a diagnosis of non small cell lung cancer?
GRACE has partnered with Clinical Care Options to develop an interactive online tool to help you understand more about your disease and treatment options. Answer a series of multiple-choice questions and then get treatment options chosen by the 5 lung cancer experts listed below.
Comments
_________________________________
Stage 4 ROS1+ [mucinous BAC] adenocarcinoma NSCLC since 2011
Xalkori (crizotinib) 5 yrs
Alimta (pemetrexed) + carboplatin (mere months)
TPX-0005 (repotrectinib) TBD (1+ years as of Fall 2018)